查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446992

到 2030 年急性细菌性皮肤和皮肤结构感染市场预测 - 按感染类型、诊断类型、治疗、给药途径、配销通路和地理位置进行的全球分析

Acute Bacterial Skin & Skin Structure Infection Market Forecasts to 2030 - Global Analysis By Infection Type, Diagnostic Type, Treatment, Route of Administration, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球急性细菌性皮肤和皮肤结构感染市场规模为 117.0832 亿美元，预计到 2030 年将达到 252.431 亿美元，预测期内CAGR为 11.6%。急性细菌性皮肤和皮肤结构感染 (ABSSSI) 是指影响皮肤和皮下组织的一系列细菌感染，通常由金黄色葡萄球菌和化脓性链球菌引起。这些感染表现为感染部位发红、发热、肿胀和疼痛等症状。 ABSSSI 的范围可以从轻微的蜂窝性组织炎到更严重的情况，如脓肿或伤口感染。及时诊断和治疗对于预防 ABSSSI 病例的併发症和促进癒合至关重要。

根据 2022 年 8 月发表在《国际抗菌药物杂誌》上的一项研究，美国近 10% 的入院病例和欧洲医院治疗的所有感染中约 15% 是由 ABSSSI 引起的。

市场动态：

司机：

增加医疗保健支出

不断增长的医疗保健支出促进了旨在为 ABSSSI 开发创新疗法和诊断工具的研究和开发工作。随着医疗保健预算的增加，医疗保健系统有能力实施先进的诊断技术，例如分子检测和即时检测。此外，支出的增加使得针对抗生素抗药性细菌的新疗法的开发和采用成为可能，这进一步推动了该市场的发展。

克制：

医疗基础设施不足

有限的医疗设施和资源可能导致医院和诊所过度拥挤，进一步加剧医疗保健系统的压力并降低优质护理的提供。如果没有适当的伤口护理、无菌操作和抗生素管理设施，管理 ABSSSI 病例将变得更具挑战性，并可能增加併发症和治疗失败的风险。此外，医疗基础设施不足可能会进一步阻碍这个市场。

机会：

诊断学的进步

技术创新彻底改变了传染病诊断领域，能够更快、更准确、更有效率地识别致病病原体。这些诊断技术的进步不仅可以透过早期准确诊断 ABSSSI 来改善患者的治疗效果，还可以透过优化抗生素的使用和降低抗生素抗药性的风险来促进抗菌药物管理工作，从而逐渐推动这一市场的成长。

威胁：

认识和诊断有限

医疗保健提供者和患者对 ABSSSI 症状、危险因素和适当的管理策略缺乏认识，导致寻求医疗护理的延误、误诊或抗生素的不当使​​用。此外，医疗保健提供者对 ABSSSI 的认识有限可能会导致诊断错误；因此，患者可能会出现併发症、疾病进展和医疗费用增加，阻碍该市场的扩张。

Covid-19 影响

COVID-19 大流行对急性细菌性皮肤和皮肤结构感染（ABSSSI）市场产生了一些负面影响。在大流行期间，医疗保健资源被转移到管理 COVID-19 患者上，导致非紧急手术、择期手术和常规就诊的延误。此外，大流行的经济影响，包括失业、医疗保健预算减少和供应链中断，对患者和医疗保健系统造成了财务限制，从而阻碍了这个市场。

在预测期内，医院获得的部分预计将是最大的

据估计，医院获得的部分占据最大份额。它是指患者在住院或前往医疗机构就诊期间所获得的感染。与社区获得性感染相比，医院获得性 ABSSSI 通常涉及更广泛的细菌。此外，医疗保健提供者必须仔细考虑抗生素的选择，并可能采用广谱药物或联合疗法来有效治疗这些感染，从而显着促进该细分市场的扩张。

革兰氏染色领域预计在预测期内CAGR最高

革兰氏染色部分预计在预测期内具有最高的CAGR，因为它是一种用于根据细胞壁组成对细菌进行分类的诊断技术。革兰氏染色涉及使用结晶紫和碘，将细菌分为两大类：革兰氏阳性菌和革兰氏阴性菌。此外，革兰氏染色技术的进步，例如快速自动化系统和即时检测设备，正在推动该领域的成长。

占比最大的地区：

由于医疗保健环境多样化以及各国感染流行模式不同，亚太地区在推断期内占据了最大的市场份额。该地区强大的医疗基础设施和对实证医学的重视推动了对 ABSSSI 创新治疗和诊断解决方案的需求。此外，利害关係人之间的合作推动创新、临床研究和先进诊断技术的采用，从而推动该地区的扩张。

复合CAGR最高的地区：

由于欧洲更加重视提高诊断能力、加强感染预防措施以及开发新疗法来应对不断上升的 ABSSSI 发病率，预计欧洲在预测期内将出现最高的CAGR。该地区是一些主要参与者的所在地，例如Melinta Therapeutics, Inc.、Melinta Therapeutics, Inc. 和辉瑞公司(Pfizer, Inc.)。因此，它为公司提供了重要的机会来创新、扩大产品范围、为改善患者状况做出贡献成果，并推动该地区的成长。

主要进展：

2024 年 1 月，Glenmark Pharmaceuticals Ltd. 宣布成立联盟 - Ichnos Glenmark Innovation - 以加速癌症治疗新药的发现。

2023 年 12 月，辉瑞公司公布了 2b 期临床试验的主要资料，该试验调查其口服胰高血糖素样肽 1 受体激动剂候选药物 danuglipron，用于治疗肥胖且无 2 型糖尿病的成年人。

2023 年 9 月，Glenmark Pharmaceuticals Limited 与 Nirma Limited 签订最终协议，以总代价剥离其子公司 Glenmark Life Sciences Limited（「GLS」）75% 的股权，但须视成交调整而定。

我们的报告提供了什么：

  • 区域和国家层面的市场份额评估
  • 对新进入者的策略建议
  • 涵盖2021年、2022年、2023年、2026年及2030年的市场资料
  • 市场趋势（驱动因素、限制因素、机会、威胁、挑战、投资机会和建议）
  • 根据市场预测提出关键业务部门的策略建议
  • 竞争性景观美化绘製主要共同趋势
  • 公司概况，包括详细的策略、财务状况和最新发展
  • 反映最新技术进步的供应链趋势

免费客製化产品：

本报告的所有客户都将有权获得以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 个）
    • 关键参与者的 SWOT 分析（最多 3 个）
  • 区域细分
    • 根据客户的兴趣对任何主要国家的市场估计、预测和CAGR（註：取决于可行性检查）
  • 竞争基准化分析
    • 根据产品组合、地理分布和策略联盟对主要参与者基准化分析

目录

第 1 章：执行摘要

第 2 章：前言

  • 抽象的
  • 股东
  • 研究范围
  • 研究方法论
    • 资料探勘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二手研究来源
    • 假设

第 3 章：市场趋势分析

  • 介绍
  • 司机
  • 限制
  • 机会
  • 威胁
  • 新兴市场
  • Covid-19 的影响

第 4 章：波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争竞争

第 5 章：全球急性细菌性皮肤和皮肤结构感染市场：依感染类型

  • 介绍
  • 社区获得性
  • 医院获得性
  • 其他感染类型

第 6 章：全球急性细菌性皮肤和皮肤结构感染市场：依诊断类型

  • 介绍
  • 临床诊断
  • 革兰氏染色
  • 血液检查
  • 生物标记检测
  • 分子诊断
  • 微生物培养
  • 其他诊断类型

第 7 章：全球急性细菌性皮肤和皮肤结构感染市场：依治疗方法

  • 介绍
  • 特地唑胺
  • 德拉沙星
  • 达托霉素
  • 万古霉素
  • 替加环素
  • 头孢洛林酯
  • 利奈唑胺
  • 奥利万星
  • 其他治疗

第 8 章：全球急性细菌性皮肤和皮肤结构感染市场：依给药途径

  • 介绍
  • 注射用
  • 专题
  • 口服

第 9 章：全球急性细菌性皮肤和皮肤结构感染市场：按配销通路

  • 介绍
  • 零售药局
  • 医院药房
  • 网路药局
  • 其他分销管道

第 10 章：全球急性细菌性皮肤和皮肤结构感染市场：按地理位置

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿联酋
    • 卡达
    • 南非
    • 中东和非洲其他地区

第 11 章：主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 扩充
  • 其他关键策略

第 12 章：公司概况

  • Paratek Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Cumberland Pharmaceuticals Inc.
  • Allergan
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Melinta Therapeutics, Inc.
  • Glenmark Pharmaceuticals Ltd
  • Endo Pharmaceuticals Inc.
  • Nabriva Therapeutics PLC
  • Basilea Pharmaceutica Ltd
  • Cipher Pharmaceuticals
  • Menarini Group
  • Sandoz Inc.
Product Code: SMRC25253

According to Stratistics MRC, the Global Acute Bacterial Skin & Skin Structure Infection Market is accounted for $11,708.32 million in 2023 and is expected to reach $25,243.1 million by 2030 growing at a CAGR of 11.6% during the forecast period. Acute Bacterial Skin and Skin Structure Infection (ABSSSI) refers to a range of bacterial infections affecting the skin and underlying tissues, commonly caused by Staphylococcus aureus and Streptococcus pyogenes. These infections manifest with symptoms like redness, warmth, swelling, and pain at the site of infection. ABSSSIs can range from mild cellulitis to more severe conditions like abscesses or wound infections. Prompt diagnosis and treatment are crucial to prevent complications and promote healing in ABSSSI cases.

According to a study published in the International Journal of Antimicrobial Agents in August 2022, almost 10% of all hospital admissions in the United States and around 15% of all infections treated in European hospitals are due to ABSSSIs.

Market Dynamics:

Driver:

Increasing healthcare expenditure

Rising healthcare expenditures foster research and development efforts aimed at developing innovative therapies and diagnostic tools for ABSSSI. With higher healthcare budgets, healthcare systems can afford to implement advanced diagnostic techniques, such as molecular testing and point-of-care testing. Additionally, increased expenditure allows for the development and adoption of novel therapies targeting antibiotic-resistant bacteria, which is propelling this market further.

Restraint:

Inadequate healthcare infrastructure

Limited healthcare facilities and resources can lead to overcrowding in hospitals and clinics, further exacerbating the strain on the healthcare system and decreasing the delivery of quality care. Without proper facilities for wound care, sterile procedures, and antibiotic administration, managing ABSSSI cases becomes more challenging and may increase the risk of complications and treatment failures. Moreover, inadequate healthcare infrastructure can hinder this market further.

Opportunity:

Advancements in diagnostics

Technological innovations have revolutionized the field of infectious disease diagnosis, enabling faster, more accurate, and more efficient identification of causative pathogens. These advancements in diagnostics not only improve patient outcomes by enabling early and accurate diagnosis of ABSSSI but also contribute to antimicrobial stewardship efforts by optimizing antibiotic use and reducing the risk of antibiotic resistance, which gradually boosts this market growth.

Threat:

Limited awareness and diagnosis

A lack of awareness among both healthcare providers and patients about ABSSSI symptoms, risk factors, and appropriate management strategies leads to delays in seeking medical care, misdiagnosis, or inappropriate use of antibiotics. Moreover, limited awareness of ABSSSI among healthcare providers may contribute to diagnostic errors; as a consequence, patients may experience complications, disease progression, and increased healthcare costs, thereby hampering this market expansion.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the Acute Bacterial Skin and Skin Structure Infection (ABSSSI) market. During the pandemic, healthcare resources were diverted towards managing COVID-19 patients, leading to delays in non-emergency procedures, elective surgeries, and routine medical visits. Furthermore, the economic repercussions of the pandemic, including job losses, reduced healthcare budgets, and supply chain disruptions, have created financial constraints for patients and healthcare systems, which hindered this market.

The hospital-acquired segment is expected to be the largest during the forecast period

The hospital-acquired segment is estimated to hold the largest share. It refers to infections that patients acquire during their hospital stay or healthcare facility visit. Hospital-acquired ABSSSI often involves a broader spectrum of bacteria compared to community-acquired infections. Additionally, healthcare providers must carefully consider the choice of antibiotics and may resort to broad-spectrum agents or combination therapy to effectively treat these infections, which significantly boosts this segment's expansion.

The gram staining segment is expected to have the highest CAGR during the forecast period

The gram staining segment is anticipated to have highest CAGR during the forecast period due to the fact that it is a diagnostic technique used to categorize bacteria based on their cell wall composition. Gram staining involves the application of crystal violet and iodine, which differentiates bacteria into two main groups: gram-positive and gram-negative. Moreover, advancements in Gram staining techniques, such as rapid automated systems and point-of-care testing devices, are driving growth within this segment.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a diverse healthcare landscape and varying patterns of infection prevalence across countries. The region's robust healthcare infrastructure and emphasis on evidence-based medicine drive demand for innovative treatments and diagnostic solutions for ABSSSI. Furthermore, collaborations between stakeholders drive innovation, clinical research, and the adoption of advanced diagnostic technologies, thereby driving this region's expansion.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to an increased focus on improving diagnostic capabilities, enhancing infection prevention measures, and developing novel therapeutics to address the rising incidence of ABSSSI. This region is home to some of the major players, such as Melinta Therapeutics, Inc., Melinta Therapeutics, Inc., and Pfizer, Inc. Therefore, it presents significant opportunities for companies to innovate, expand their product offerings, contribute to improving patient outcomes, and drive the region's growth.

Key players in the market

Some of the key players in the Acute Bacterial Skin & Skin Structure Infection Market include Paratek Pharmaceuticals, Inc., Merck & Co., Inc., Cumberland Pharmaceuticals Inc., Allergan, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Glenmark Pharmaceuticals Ltd, Endo Pharmaceuticals Inc., Nabriva Therapeutics PLC, Basilea Pharmaceutica Ltd, Melinta Therapeutics, Inc., Menarini Group and Sandoz Inc.

Key Developments:

In January 2024, Glenmark Pharmaceuticals Ltd. announced the launch of their alliance - Ichnos Glenmark Innovation - to accelerate new drug discovery in cancer treatment.

In December 2023, Pfizer Inc. announced topline data from the Phase 2b clinical trial investigating its oral Glucagon-like peptide-1 receptor agonist candidate, danuglipron, in adults with obesity and without type 2 diabetes.

In September 2023, Glenmark Pharmaceuticals Limited has entered into a definitive agreement with Nirma Limited to divest 75% stake in its subsidiary, Glenmark Life Sciences Limited ("GLS"), for an aggregate consideration, subject to closing adjustments.

Infection Types Covered:

  • Community-Acquired
  • Hospital-Acquired
  • Other Infection Types

Diagnostic Types Covered:

  • Clinical Diagnosis
  • Gram Staining
  • Blood Tests
  • Biomarker Assays
  • Molecular Diagnostics
  • Microbiological Cultures
  • Other Diagnostic Types

Treatments Covered:

  • Tedizolid
  • Delafloxacin
  • Daptomycin
  • Vancomycin
  • Tigecycline
  • Ceftaroline fosamil
  • Linezolid
  • Oritavancin
  • Other Treatments

Route of Administration Covered:

  • Parenteral
  • Topical
  • Oral

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Acute Bacterial Skin & Skin Structure Infection Market, By Infection Type

  • 5.1 Introduction
  • 5.2 Community-Acquired
  • 5.3 Hospital-Acquired
  • 5.4 Other Infection Types

6 Global Acute Bacterial Skin & Skin Structure Infection Market, By Diagnostic Type

  • 6.1 Introduction
  • 6.2 Clinical Diagnosis
  • 6.3 Gram Staining
  • 6.4 Blood Tests
  • 6.5 Biomarker Assays
  • 6.6 Molecular Diagnostics
  • 6.7 Microbiological Cultures
  • 6.8 Other Diagnostic Types

7 Global Acute Bacterial Skin & Skin Structure Infection Market, By Treatment

  • 7.1 Introduction
  • 7.2 Tedizolid
  • 7.3 Delafloxacin
  • 7.4 Daptomycin
  • 7.5 Vancomycin
  • 7.6 Tigecycline
  • 7.7 Ceftaroline fosamil
  • 7.8 Linezolid
  • 7.9 Oritavancin
  • 7.10 Other Treatments

8 Global Acute Bacterial Skin & Skin Structure Infection Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Parenteral
  • 8.3 Topical
  • 8.4 Oral

9 Global Acute Bacterial Skin & Skin Structure Infection Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Retail Pharmacies
  • 9.3 Hospital Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Other Distribution Channels

10 Global Acute Bacterial Skin & Skin Structure Infection Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Paratek Pharmaceuticals, Inc.
  • 12.2 Merck & Co., Inc.
  • 12.3 Cumberland Pharmaceuticals Inc.
  • 12.4 Allergan
  • 12.5 Pfizer Inc.
  • 12.6 Teva Pharmaceutical Industries Ltd.
  • 12.7 Melinta Therapeutics, Inc.
  • 12.8 Glenmark Pharmaceuticals Ltd
  • 12.9 Endo Pharmaceuticals Inc.
  • 12.10 Nabriva Therapeutics PLC
  • 12.11 Basilea Pharmaceutica Ltd
  • 12.12 Cipher Pharmaceuticals
  • 12.13 Menarini Group
  • 12.14 Sandoz Inc.

List of Tables

  • Table 1 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Infection Type (2021-2030) ($MN)
  • Table 3 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Community-Acquired (2021-2030) ($MN)
  • Table 4 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Hospital-Acquired (2021-2030) ($MN)
  • Table 5 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Infection Types (2021-2030) ($MN)
  • Table 6 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Diagnostic Type (2021-2030) ($MN)
  • Table 7 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Clinical Diagnosis (2021-2030) ($MN)
  • Table 8 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Gram Staining (2021-2030) ($MN)
  • Table 9 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 10 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Biomarker Assays (2021-2030) ($MN)
  • Table 10 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 11 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Microbiological Cultures (2021-2030) ($MN)
  • Table 12 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Diagnostic Types (2021-2030) ($MN)
  • Table 14 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 15 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Tedizolid (2021-2030) ($MN)
  • Table 16 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Delafloxacin (2021-2030) ($MN)
  • Table 17 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Daptomycin (2021-2030) ($MN)
  • Table 18 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Vancomycin (2021-2030) ($MN)
  • Table 19 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Tigecycline (2021-2030) ($MN)
  • Table 20 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Ceftaroline fosamil (2021-2030) ($MN)
  • Table 21 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Linezolid (2021-2030) ($MN)
  • Table 22 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Oritavancin (2021-2030) ($MN)
  • Table 23 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 24 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 25 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 26 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Topical (2021-2030) ($MN)
  • Table 27 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Oral (2021-2030) ($MN)
  • Table 28 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 29 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 30 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 31 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 32 Global Acute Bacterial Skin & Skin Structure Infection Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Table Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.